Status:
COMPLETED
Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Pfizer
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The aim of this study is to examine the effect of intensive cholesterol lowering therapy and tight blood pressure (BP) regulation on endothelial function (inner cell layer of vessels that determines d...
Detailed Description
Background:The prevalence of diagnosed type 2 diabetes mellitus (DM) is estimated to 2-4% in the general population in most European countries. DM is associated with an increased frequency of manifest...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus,
- Total cholesterol \<6.5 mmol/l
- Signed informed consent
Exclusion
- Documented CAD or peripheral vascular disease
- Treatment with lipid-lowering drugs
- Contraindications to HMG-CoA reductase therapy
- Potential noncompliance
Key Trial Info
Start Date :
July 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00124397
Start Date
July 1 2001
End Date
December 1 2004
Last Update
August 5 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Research
SHF Svendborg, Svendborg, Denmark, 5700